Hansen Pharmaceutical reported revenue of 1.039 billion yuan in 2025, an increase of 3.41%, while net profit fell by 10.05% to 198 million yuan. However, cash flow surged by 87.62%.

The company’s revenue grew by 3.41% year-on-year to RMB 1.039 billion in 2025, but net profit attributable to shareholders declined by 10.05% due primarily to a significant increase in selling expenses (+7.49%), which exceeded revenue growth and diluted profitability. Despite an improvement in gross margin, the net margin fell, reflecting rigid cost pressures. The high concentration of core products, with the Southwest region surpassing the East China region in contribution, and operating cash flow surging by 87.62%, underscored the stability and resilience of its fundamental operations.

lanjinger.comApr 28 14:13

Express News | Midday Review: ChiNext Index Down 0.54% in First Half of Day; Pharmaceutical Sector Rises Against the Trend

BreakingsApr 28 11:32

Express News | 10:30 AM Quick Review: Divergence in Sector Rotation, Defensive Sectors Show Active Performance

BreakingsApr 28 10:33

Hansen Pharmaceutical: First Quarter Report for 2026

SZSIApr 28 00:00 · Announcements

Hansen Pharmaceutical: 2025 Annual Report

SZSIApr 28 00:00 · Announcements

Hansen Pharmaceutical: Summary of the 2025 Annual Report

SZSIApr 28 00:00 · Announcements